Shots:
- The P-III COV-BARRIER study involves assessing Baricitinib (4mg, qd) + SoC (which included 79% receiving corticosteroids and 19% receiving remdesivir, with some receiving both) vs PBO + SoC in 1525 patients in a ratio (1:1) hospitalized with COVID-19
- The trial did not meet 1EPs i.e. progression to non-invasive ventilation or invasive mechanical ventilation including ECMO or death by Day 28 (17.5% vs 29.4%). The data showed a 38% reduction in mortality by Day 28
- Lilly plans to publish the data in a peer-reviewed journal in the coming mos. and share the data with regulatory authorities in the US, EU, and other geographies
Click here to read full press release/ article | Ref: Newswire Canada | Image: The Indian Express
The post Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19 first appeared on PharmaShots.
